Intended for healthcare professionals

Letters Access to Tamiflu trials

Roche continues to drag its feet on access to Tamiflu data

BMJ 2013; 346 doi: (Published 15 May 2013) Cite this as: BMJ 2013;346:f3001
  1. Peter C Gøtzsche, professor1
  1. 1Nordic Cochrane Centre, Rigshospitalet, Denmark
  1. pcg{at}

Four years after it was first promised (but not fulfilled), Roche is again offering Cochrane researchers access to its trial reports on Tamiflu. But Roche is offering less than full transparency: “In line with European Union law, each CSR [clinical study report] will be edited by Roche to ensure patient confidentiality and to protect legitimate commercial interests.”1 Furthermore, Roche says …

View Full Text

Log in

Log in through your institution


* For online subscription